Image quality and accuracy

Efficacy and image accuracy of Rapiscan were determined relative to adenosine in two randomised, double-blind studies.

ADenoscan® (adenosine injection) Versus RegAdenosoN Comparative Evaluation for Myocardial Perfusion Imaging (ADVANCE MPI 1 and ADVANCE MPI 2) in 2,015 patients with known or suspected coronary artery disease who were referred for a clinically-indicated pharmacologic stress MPI. View Phase 3 trials

Comparative clinical assessments of Rapiscan and adenosine images include

  1. Image quality1,2
  2. Presence/absence of reversible perfusion defect1,2
  3. Side by side visual analysis of the extent of ischemia2
  4. Representative patient example3


  1. Cerqueira MD, Nguyen P, Staehr P, et al, on behalf of the ADVANCE MPI Trial Investigators. Effects of age, gender, obesity and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine: integrated ADVANCE MPI trial results. J Am Coll Cardiol 2008;1:307-316
  2. Iskandrian AE, Bateman TM, Belardinelli L, et al. Adenosine versus Rapiscan comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol 2007;14:645-658 (View abstract)
  3. Zoghbi G and Iskandrian A. Regadenoson Myocardial Perfusion Imaging. Imaging Med 2010; 2:395-406.